| Bioactivity | APOL1-IN-1 is a apolipoprotein L1 (APOL1) inhibitor extracted from patent WO2020131807A1 compound 87. APOL1-IN-1 can be used for the research of focal segmental glomerulosclerosis (FSGS) and non-diabetic kidney disease (NDKD)[1]. | |||||||||
| Target | Apolipoprotein LI (APOL1) | |||||||||
| Name | APOL1-IN-1 | |||||||||
| CAS | 2446817-72-5 | |||||||||
| Formula | C21H20FN3O3 | |||||||||
| Molar Mass | 381.40 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Brodney M, et, al. Inhibitors of apol1 and methods of using same. WO2020131807A1. |
APOL1-IN-1
CAS: 2446817-72-5 F: C21H20FN3O3 W: 381.40
APOL1-IN-1 is a apolipoprotein L1 (APOL1) inhibitor extracted from patent WO2020131807A1 compound 87. APOL1-IN-1 can be
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.